Plasma Adiponectin Is Associated with Plasma Brain Natriuretic Peptide and Cardiac Function in Healthy Subjects

Abstract

The aim of this study was to evaluate the relationship between the plasma adiponectin level, plasma brain natriuretic peptide (BNP) level, and cardiac function in healthy subjects. We obtained clinical data and performed blood tests, including measurement of the plasma adiponectin and BNP levels, in 1,538 healthy persons from Arita-cho, a rural area of Japan. Six hundred and eight subjects also underwent echocardiography. There was a significant positive correlation between their plasma BNP and adiponectin levels in simple regression analysis (standardized regression coefficient [β]=0.34). Multivariate regression analysis revealed that the plasma adiponectin level was independently associated with the plasma BNP level (β=0.12), as well as with the age (β=0.22), male gender (β=−0.26), waist circumference (β=−0.16), and the plasma levels of high-density lipoprotein cholesterol (β=0.13), triglycerides (β=−0.16), aspartate aminotransferase (β=0.08), γ-glutamyl transpeptidase (β=−0.10), uric acid (β=−0.07), and creatinine (β=0.08). We also found a link between plasma adiponectin and the left atrial diameter index (β=0.08) or left ventricular diameter index (β=0.11), even after adjustment for age, sex, and body mass index. The plasma adiponectin level increased along with an increase of plasma BNP in healthy subjects independently of other confounding factors, demonstrating that adiponectin reflects cardiac function.

References

  1. 1

    Santaniemi M, Kesaniemi YA, Ukkola O : Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocrinol 2006; 155: 745–750.

  2. 2

    Arita Y, Kihara S, Ouchi N, et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79–83.

  3. 3

    Hotta K, Funahashi T, Arita Y, et al: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595–1599.

  4. 4

    Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P : Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006; 110: 267–278.

  5. 5

    Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB : Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730–1737.

  6. 6

    Liao Y, Takashima S, Maeda N, et al: Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005; 67: 705–713.

  7. 7

    Ouchi N, Shibata R, Walsh K : Cardioprotection by adiponectin. Trends Cardiovasc Med 2006; 16: 141–146.

  8. 8

    Shibata R, Ouchi N, Ito M, et al: Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004; 10: 1384–1389.

  9. 9

    George J, Patal S, Wexler D, et al: Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006; 92: 1420–1424.

  10. 10

    Kistorp C, Faber J, Galatius S, et al: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756–1762.

  11. 11

    Pilz S, Mangge H, Wellnitz B, et al: Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 2006; 91: 4277–4286.

  12. 12

    von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D : Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem 2006; 52: 853–859.

  13. 13

    Mukoyama M, Nakao K, Hosoda K, et al: Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402–1412.

  14. 14

    Tsutamoto T, Wada A, Maeda K, et al: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509–516.

  15. 15

    Wang TJ, Larson MG, Levy D, et al: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655–663.

  16. 16

    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC : Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

  17. 17

    Mosteller RD : Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.

  18. 18

    Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450–458.

  19. 19

    Kitabatake A, Inoue M, Asao M, et al: Transmitral blood flow reflecting diastolic behavior of the left ventricle in health and disease—a study by pulsed Doppler technique. Jpn Circ J 1982; 46: 92–102.

  20. 20

    Wang TJ, Larson MG, Levy D, et al: Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594–600.

  21. 21

    Tsutamoto T, Wada A, Sakai H, et al: Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2006; 47: 582–586.

  22. 22

    Zoccali C, Mallamaci F, Tripepi G, et al: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134–141.

  23. 23

    Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS : Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007; 115: 1345–1353.

  24. 24

    Kimura Y, Tomiyama H, Nishikawa E, et al: Characteristics of cardiovascular morphology and function in the high-normal subset of hypertension defined by JNC-VI recommendations. Hypertens Res 1999; 22: 291–295.

  25. 25

    Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D : Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension 1995; 25: 1155–1160.

  26. 26

    Pineiro R, Iglesias MJ, Gallego R, et al: Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 2005; 579: 5163–5169.

  27. 27

    D'Souza SP, Yellon DM, Martin C, et al: B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003; 284: H1592–H1600.

  28. 28

    Nishikimi T, Maeda N, Matsuoka H : The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2006; 69: 318–328.

  29. 29

    Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP : Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–1566.

  30. 30

    Asakawa M, Takano H, Nagai T, et al: Peroxisome proliferator−activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002; 105: 1240–1246.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Masafumi Kitakaze.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ohara, T., Kim, J., Asakura, M. et al. Plasma Adiponectin Is Associated with Plasma Brain Natriuretic Peptide and Cardiac Function in Healthy Subjects. Hypertens Res 31, 825–831 (2008). https://doi.org/10.1291/hypres.31.825

Download citation

Keywords

  • adiponectin
  • brain natriuretic peptide
  • population based study
  • echocardiography

Further reading